Menu Search
Equities

CANbridge Pharmaceuticals Inc

MF1:DEU

CANbridge Pharmaceuticals Inc

Actions
  • Price (EUR)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year CANbridge Pharmaceuticals Inc grew revenues 30.26% from 78.97m to 102.87m. Additionally the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as percentages of sales). These changes narrowed profitability losses from -483.48m to -378.84m.
Gross margin63.97%
Net profit margin-389.95%
Operating margin-381.29%
Return on assets-99.74%
Return on equity--
Return on investment-1,160.07%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at CANbridge Pharmaceuticals Inc fell by 326.26m. Cash Flow from Investing was negative at 26.86m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 278.23m for operations while cash used for financing totalled 28.02m.
Cash flow per share-0.9724
Price/Cash flow per share--
Book value per share-0.7178
Tangible book value per share-0.9012
More ▼

Balance sheet in CNYView more

CANbridge Pharmaceuticals Inc uses little or no debt in its capital structure.
Current ratio0.245
Quick ratio0.2146
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.